Short time administration of antirheumatic drugs - Methotrexate as a strong inhibitor of osteoblast's proliferation in vitro

INTRODUCTION: Due to increasing use of disease modifying antirheumatic drugs (DMARDs) as first line therapy in rheumatic diseases, dental and maxillofacial practitioner should be aware of drug related adverse events. Especially effects on bone-metabolism and its cells are discussed controversially....

Descripción completa

Detalles Bibliográficos
Autores principales: Annussek, Tobias, Kleinheinz, Johannes, Thomas, Szuwart, Joos, Ulrich, Wermker, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517327/
https://www.ncbi.nlm.nih.gov/pubmed/23021595
http://dx.doi.org/10.1186/1746-160X-8-26

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3517327/
https://www.ncbi.nlm.nih.gov/pubmed/23021595
http://dx.doi.org/10.1186/1746-160X-8-26

Ejemplares similares